Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma



Status:Completed
Conditions:Blood Cancer, Hematology
Therapuetic Areas:Hematology, Oncology
Healthy:No
Age Range:18 - Any
Updated:4/5/2019
Start Date:March 2012
End Date:August 2018

Use our guide to learn which trials are right for you!

A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma

The primary objective of this study is to determine the efficacy of PCI-32765, both as a
single agent and in combination with dexamethasone, in subjects with relapsed or relapsed and
refractory Multiple Myeloma (MM)

Bruton's tyrosine kinase (Btk) is an enzyme that is present in hematopoietic cells other than
T cells and is necessary for downstream signal transduction from various hematopoietic
receptors including the B cell receptor as well as some Fc, chemokine, and adhesion
receptors, and is crucial for both B cell development and osteoclastogenesis. Although
down-regulated in normal plasma cells, Btk is highly expressed in the malignant cells from
many myeloma patients and some cell lines. PCI 32765 is a potent and specific inhibitor of
Btk currently in Phase 2 clinical trials. The current study is designed and intended to
determine the effects of PCI-32765 in subjects with MM.

Inclusion Criteria:

- Diagnosis of symptomatic MM with measurable disease, defined here as having at least
one of the following:

1. Serum monoclonal protein (M-protein) ≥0.5 g/dL as determined by serum protein
electrophoresis (SPEP)

2. Urine M-protein ≥200 mg/24 hrs

3. Serum free light chain (FLC) assay: involved FLC level ≥10 mg/dL (≥100 mg/L)
provided serum FLC ratio is abnormal

- Relapsed or relapsed and refractory MM after receiving at least 2 but no more than 5
previous lines of therapy, 1 of which must be an immunomodulator.

- Refractory myeloma (to most recent treatment) is defined as disease that is
nonresponsive while on treatment or progressive disease within 60 days after the
completion of preceding treatment. Nonresponsive disease is defined as either failure
to achieve minimal response or development of progressive disease while on therapy.

- Men and women ≥18 years of age.

- ECOG performance status of ≤ 1.

Exclusion Criteria:

- Subject must not have primary refractory disease defined as disease that is
nonresponsive in subjects who have never achieved a minor response (MR) or better with
any therapy.

- Polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS)
syndrome, osteosclerotic myeloma, or Crow-Fukase syndrome.

- Plasma cell leukemia.

- Primary amyloidosis.

- Certain exclusions on prior therapy.

- ANC <0.75 x 10^9/L independent of growth factor support.

- Platelets <50 x 10^9/L) independent of transfusion support.

- AST or ALT ≥3.0 x upper limit of normal (ULN).

- Total bilirubin >2.5 x ULN, unless due to Gilbert's syndrome.

- Creatinine >2.5 mg/dL.

- Unable to swallow capsules or disease significantly affecting gastrointestinal
function.

- Requires anti-coagulation with warfarin or a vitamin K antagonist. Requires treatment
with strong CYP3A4/5 inhibitors.
We found this trial at
10
sites
?
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
?
mi
from
Nashville, TN
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials